Compare Bristol-Myers Squibb Co (BMY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Inovio Pharmaceuticals Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $95.85M). The key difference: Bristol-Myers Squibb Co is far larger — about 1213.4× Inovio Pharmaceuticals Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BMY | INO | |
|---|---|---|
Market Cap | $116.30B | $95.85M |
Sector | Health | Health |
52-Week High | $62.37 | $2.87 |
52-Week Low | $42.60 | $1.05 |
Enterprise Value | $152.24B | $66.86M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
